

CHART INDUSTRIES INC

Form 10-Q

November 13, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2007**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number 1-11442  
CHART INDUSTRIES, INC.**

(Exact Name of Registrant as Specified in its Charter)

Delaware

34-1712937

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

One Infinity Corporate Centre Drive, Suite 300, Garfield Heights, Ohio 44125  
(Address of Principal Executive Offices) (ZIP Code)

Registrant's Telephone Number, Including Area Code: (440) 753-1490

NOT APPLICABLE

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  No

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13, or 15 of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes  No

At October 31, 2007 there were 28,055,046 outstanding shares of the Company's Common Stock, par value \$0.01 per share.

**CHART INDUSTRIES, INC.**  
**INDEX**

|  | Page |
|--|------|
| <b><u>Part I. Financial Information</u></b>  |      |
| <u>Item 1. Financial Statements</u>  |      |
| <u>Condensed Consolidated Balance Sheets as of September 30, 2007 and December 31, 2006</u>                            | 3    |
| <u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2007 and 2006</u> | 4    |
| <u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2007 and 2006</u>           | 5    |
| <u>Notes to Unaudited Condensed Consolidated Financial Statements</u>  | 6    |
| <u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                   | 21   |
| <u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>  | 29   |
| <u>Item 4. Controls and Procedures</u>   | 29   |
| <b><u>Part II. Other Information</u></b>   |      |
| <u>Item 1A. Risk Factors</u>   | 30   |
| <u>Item 6. Exhibits</u>  | 31   |
| <u>Signatures</u>  | 32   |
| <u>EX-31.1</u>   |      |
| <u>EX-31.2</u>   |      |
| <u>EX-32.1</u>   |      |
| <u>EX-32.2</u>   |      |

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Dollars in thousands, except per share amounts)

|  | <b>September<br/>30,<br/>2007</b> | <b>December<br/>31,<br/>2006</b> |
|--|-----------------------------------|----------------------------------|
|  | (Unaudited)                       |                                  |
| <b>ASSETS</b>  |                                   |                                  |
| Current Assets   |                                   |                                  |
| Cash and cash equivalents  | \$ 62,426                         | \$ 18,854                        |
| Accounts receivable, net   | 79,064                            | 76,762                           |
| Inventories, net   | 84,021                            | 72,857                           |
| Unbilled contract revenue  | 26,489                            | 32,993                           |
| Other current assets   | 22,591                            | 26,085                           |
| Assets held for sale   | 3,084                             | 3,084                            |
| <br>Total Current Assets   | <br>277,675                       | <br>230,635                      |
| <br>Property, plant and equipment, net   | <br>96,589                        | <br>85,723                       |
| Goodwill   | 247,049                           | 247,144                          |
| Identifiable intangible assets, net  | 138,322                           | 146,623                          |
| Other assets, net  | 13,087                            | 14,750                           |
| <br><b>TOTAL ASSETS</b>  | <br><b>\$ 772,722</b>             | <br><b>\$ 724,875</b>            |
| <br><b>LIABILITIES AND SHAREHOLDERS EQUITY</b>   |                                   |                                  |
| Current Liabilities  |                                   |                                  |
| Accounts payable   | \$ 50,014                         | \$ 48,031                        |
| Customer advances and billings in excess of contract revenue   | 55,117                            | 45,200                           |
| Accrued expenses and other current liabilities   | 41,192                            | 45,260                           |
| Short-term debt  |                                   | 750                              |
| <br>Total Current Liabilities  | <br>146,323                       | <br>139,241                      |
| <br>Long-term debt   | <br>250,000                       | <br>290,000                      |
| Other long-term liabilities  | 70,653                            | 75,900                           |
| Shareholders Equity  |                                   |                                  |
| Common stock, par value \$.01 per share - 150,000,000 shares authorized,<br>28,021,778 and 25,588,043 shares issued and outstanding at September 30,<br>2007 and December 31, 2006, respectively | 280                               | 256                              |
| Additional paid-in capital   | 238,602                           | 185,567                          |
| Retained earnings  | 54,127                            | 26,389                           |
| Accumulated other comprehensive income   | 12,737                            | 7,522                            |

305,746 219,734

|  |            |            |
|--|------------|------------|
| <b>TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</b> | \$ 772,722 | \$ 724,875 |
|--|------------|------------|

The balance sheet at December 31, 2006 has been derived from the audited financial statements at that date, but does not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements.

See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)**  
(Dollars and shares in thousands, except per share amounts)

|  | <b>Three Months Ended</b> |             | <b>Nine Months Ended</b> |             |
|--|---------------------------|-------------|--------------------------|-------------|
|  | <b>September 30,</b>      |             | <b>September 30,</b>     |             |
|  | <b>2007</b>               | <b>2006</b> | <b>2007</b>              | <b>2006</b> |
| Sales  | \$ 163,670                | \$ 142,825  | \$ 483,720               | \$ 393,032  |
| Cost of sales  | 118,280                   | 103,385     | 347,213                  | 280,492     |
| <br>   |                           |             |                          |             |
| Gross profit   | 45,390                    | 39,440      | 136,507                  | 112,540     |
| <br>   |                           |             |                          |             |
| Selling, general and administrative expenses                     | 20,769                    | 18,208      | 68,967                   | 53,372      |
| Amortization expense   | 2,636                     | 4,290       | 8,304                    | 11,385      |
| Employee separation and plant closure costs                      | 135                       | 73          | 284                      | 304         |
| Loss on disposal of assets, net                                  | 436                       |             | 502                      |             |
|  | 23,976                    | 22,571      | 78,057                   | 65,061      |
| <br>   |                           |             |                          |             |
| Operating income   | 21,414                    | 16,869      | 58,450                   | 47,479      |
| <br>   |                           |             |                          |             |
| Other expenses (income):   |                           |             |                          |             |
| Interest expense, net  | 5,105                     | 6,125       | 17,409                   | 19,256      |
| Financing costs amortization                                     | 413                       | 393         | 1,233                    | 1,132       |
| Foreign currency expense (income)                                | (510)                     | (26)        | (221)                    | (177)       |
|  | 5,008                     | 6,492       | 18,421                   | 20,211      |
| <br>   |                           |             |                          |             |
| Income from operations before income taxes and minority interest | 16,406                    | 10,377      | 40,029                   | 27,268      |
| <br>   |                           |             |                          |             |
| Income tax expense   | 4,312                     | 3,372       | 12,368                   | 8,862       |
| <br>   |                           |             |                          |             |
| Income from operations before minority interest                  | 12,094                    | 7,005       | 27,661                   | 18,406      |
| <br>   |                           |             |                          |             |
| Minority interest, net of taxes                                  | (18)                      | 73          | (77)                     | 120         |
| <br>   |                           |             |                          |             |
| Net income   | \$ 12,112                 | \$ 6,932    | \$ 27,738                | \$ 18,286   |
| <br>   |                           |             |                          |             |
| Net income per common share basic                                | \$ 0.44                   | \$ 0.34     | \$ 1.05                  | \$ 1.45     |
| <br>   |                           |             |                          |             |
| Net income per common share diluted                              | \$ 0.42                   | \$ 0.34     | \$ 1.03                  | \$ 1.40     |

Edgar Filing: CHART INDUSTRIES INC - Form 10-Q

|   |        |        |        |        |
|---|--------|--------|--------|--------|
| Weighted average number of common shares<br>outstanding basic | 27,671 | 20,245 | 26,467 | 12,579 |
|---|--------|--------|--------|--------|

|   |        |        |        |        |
|---|--------|--------|--------|--------|
| Weighted average number of common shares<br>outstanding diluted | 28,665 | 20,398 | 27,021 | 13,107 |
|---|--------|--------|--------|--------|

See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

---

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**  
(Dollars in thousands)

|   | <b>Nine Months Ended</b> |                  |
|---|--------------------------|------------------|
|   | <b>September 30,</b>     |                  |
|   | <b>2007</b>              | <b>2006</b>      |
| <b>OPERATING ACTIVITIES</b>   |                          |                  |
| Net income  | \$ 27,738                | \$ 18,286        |
| Adjustments to reconcile net income to net cash provided by operating activities:       |                          |                  |
| Depreciation and amortization   | 13,670                   | 15,251           |
| Employee stock and stock option related compensation expense                            | 8,522                    | 1,428            |
| Financing costs amortization  | 1,233                    | 1,132            |
| Other non-cash operating activities   | 165                      | 15               |
| Increase (decrease) in cash resulting from changes in operating assets and liabilities: |                          |                  |
| Accounts receivable   | (1,544)                  | (421)            |
| Inventory   | (9,490)                  | (4,541)          |
| Unbilled contract revenues and other current assets                                     | 10,044                   | (21,608)         |
| Accounts payable and other current liabilities  | (5,747)                  | 13,609           |
| Customer advances and billings in excess of contract revenue                            | 9,567                    | 10,338           |
| <b>Net Cash Provided By Operating Activities</b>  | <b>54,158</b>            | <b>33,489</b>    |
| <b>INVESTING ACTIVITIES</b>   |                          |                  |
| Capital expenditures  | (15,575)                 | (13,479)         |
| Acquisition of business, net of cash acquired   |                          | (15,858)         |
| Acquisition of minority interest and other assets                                       | (1,612)                  | (31)             |
| <b>Net Cash Used In Investing Activities</b>  | <b>(17,187)</b>          | <b>(29,368)</b>  |
| <b>FINANCING ACTIVITIES</b>   |                          |                  |
| Net payments on revolving credit facilities or short-term debt                          | (750)                    | (2,354)          |
| Principal payments on long-term debt  | (40,000)                 | (55,000)         |
| Proceeds from initial public offering, net  |                          | 172,512          |
| Cash dividend paid  |                          | (150,313)        |
| Proceeds from exercise of warrants and options  | 3,540                    | 39,237           |
| Proceeds from secondary stock offering, net   | 38,292                   |                  |
| Contributions from joint venture partners   | 1,328                    |                  |
| Other financing activities  | 2,408                    | (854)            |
| <b>Net Cash Provided By Financing Activities</b>  | <b>4,818</b>             | <b>3,228</b>     |
| <br>  |                          |                  |
| Net increase in cash and cash equivalents   | 41,789                   | 7,349            |
| Effect of exchange rate changes on cash   | 1,783                    | 102              |
| Cash and cash equivalents at beginning of period  | 18,854                   | 11,326           |
| <b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>                                       | <b>\$ 62,426</b>         | <b>\$ 18,777</b> |



See accompanying notes to these unaudited condensed consolidated financial statements. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
**(Dollars and shares in thousands, except per share amounts)**

**NOTE A Basis of Preparation**

The accompanying unaudited condensed consolidated financial statements of Chart Industries, Inc. and its subsidiaries (the Company) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for annual financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2006. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007.

*Principles of Consolidation:* The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation. Investments in affiliates where the Company's ownership is between 20 percent and 50 percent, or where the Company does not have control, but has the ability to exercise significant influence over operations or financial policy, are accounted for under the equity method.

*Use of Estimates:* The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

*Nature of Operations:* The Company is a leading global supplier of standard and custom-engineered products and systems serving a wide variety of low-temperature and cryogenic applications. The Company has developed an expertise in cryogenic systems and equipment, which operate at low temperatures sometimes approaching absolute zero. The majority of the Company's products, including vacuum-insulated containment vessels, heat exchangers, cold boxes and other cryogenic components, are used throughout the liquid-gas supply chain for the purification, liquefaction, distribution, storage and end-use of industrial gases and hydrocarbons. The Company has domestic operations located in eight states, including its principal executive offices located in Garfield Heights, Ohio and an international presence in Australia, China, the Czech Republic, Germany and the United Kingdom.

*Basis of Presentation:* On June 12, 2007, the Company completed a secondary offering of 12,612,513 shares. The secondary shares were sold by FR X Chart Holdings LLC and certain members of the Company's management. As part of the shares sold by members of management, 42,421 stock options were exercised in conjunction with the offering. The option of 1,891,876 shares to cover over-allotments granted to the underwriters was exercised in full. The net proceeds of \$38,061 received by the Company from the exercise of the over-allotment option were used to make a voluntary principal payment under the term loan portion of the senior secured credit facility. The consolidated financial statements have been adjusted for the three and nine months ended September 30, 2006 to give effect to the 4.6263-for-one stock split of the Company's common stock that occurred on July 20, 2006, and related adjustments to its capital structure and stock options that were effected upon the completion of the Company's initial public offering (IPO) on July 31, 2006.

*Reclassifications:* Certain prior year amounts have been reclassified to conform to the current year presentation.

*Inventories:* Inventories are stated at the lower of cost or market with cost being determined by the first-in, first-out (FIFO) method. The components of inventory are as follows:

|                            | <b>September<br/>30,<br/>2007</b> | <b>December<br/>31,<br/>2006</b> |
|----------------------------|-----------------------------------|----------------------------------|
| Raw materials and supplies | \$ 41,516                         | \$ 32,404                        |
| Work in process            | 27,222                            | 20,974                           |
| Finished goods             | 15,283                            | 19,479                           |

\$ 84,021      \$ 72,857

*Revenue Recognition:* For the majority of the Company's products, revenue is recognized when products are shipped, title has transferred and collection is reasonably assured. For these products, there is also persuasive evidence of an arrangement, and the selling price to the buyer is fixed or determinable. For brazed aluminum heat exchangers, cold boxes, vacuum-insulated pipe, liquefied natural gas fueling stations and engineered tanks, the Company uses the percentage of completion method of accounting. Earned revenue is based on the percentage that incurred costs to date bear to total estimated costs at completion after giving effect to the most current estimates. The cumulative impact of revisions in total cost estimates during the progress of work is reflected in the period in which these changes become known. Earned revenue reflects the original contract price adjusted for agreed upon claims and change orders, if any. Losses expected to be incurred

Table of Contents

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)

**NOTE A Basis of Preparation Continued**

on contracts in process, after consideration of estimated minimum recoveries from claims and change orders, are charged to operations as soon as such losses are known. Change orders resulting in additional revenue and profit are recognized upon approval by the customer based on the percentage that incurred costs to date bear to total estimated costs at completion. Timing of amounts billed on contracts varies from contract to contract and could cause a significant variation in working capital requirements.

**Product Warranties:** The Company provides product warranties with varying terms and durations for the majority of its products. The Company records warranty expense in cost of sales. The changes in the Company's consolidated warranty reserve during the three and nine months ended September 30, 2007 and 2006 are as follows:

|                   | Three Months Ended |          | Nine Months Ended |          |
|-------------------|--------------------|----------|-------------------|----------|
|                   | September 30,      |          | September 30,     |          |
|                   | 2007               | 2006     | 2007              | 2006     |
| Beginning balance | \$ 5,353           | \$ 4,206 | \$ 4,765          | \$ 3,598 |
| Warranty expense  | 1,629              | 929      | 3,313             | 2,640    |
| Warranty usage    | (818)              | (868)    | (1,914)           | (1,971)  |
| Ending balance    | \$ 6,164           | \$ 4,267 | \$ 6,164          | \$ 4,267 |

**Goodwill and Other Intangible Assets:** In accordance with Financial Accounting Standards Board ( FASB ) Statement of Financial Accounting Standards ( SFAS ) No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets, the Company does not amortize goodwill or other indefinite lived intangible assets, but reviews them at least annually for impairment using a measurement date of October 1st. The Company amortizes intangible assets that have finite useful lives.

SFAS No. 142 requires that goodwill and other indefinite lived intangible assets be tested for impairment at the reporting unit level on an annual basis. Under SFAS No. 142, a company determines the fair value of any indefinite lived intangible assets, compares the fair value to its carrying value and records an impairment loss if the carrying value exceeds its fair value. Goodwill is tested utilizing a two-step approach. After recording any impairment losses for indefinite lived intangible assets, a company is required to determine the fair value of each reporting unit and compare the fair value to its carrying value, including goodwill, of such reporting unit (step one). If the fair value exceeds the carrying value, no impairment loss would be recognized. If the carrying value of the reporting unit exceeds its fair value, the goodwill of the reporting unit may be impaired. The amount of the impairment, if any, would then be measured in step two, which compares the implied fair value of reporting unit goodwill with the carrying amount of that goodwill.

The following table displays the gross carrying amount and accumulated amortization for all intangible assets.

|                        | Estimated Useful Life | September 30, 2007    |                          | December 31, 2006     |                          |
|------------------------|-----------------------|-----------------------|--------------------------|-----------------------|--------------------------|
|                        |                       | Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization |
| Finite-lived assets:   |                       |                       |                          |                       |                          |
| Unpatented technology  | 9 years               | \$ 9,400              | (2,212)                  | \$ 9,400              | \$ (1,364)               |
| Patents                | 10 years              | 8,138                 | (2,026)                  | 8,138                 | (1,287)                  |
| Product names          | 14 years              | 2,580                 | (413)                    | 2,580                 | (255)                    |
| Backlog                | 14 months             | 6,720                 | (6,720)                  | 6,720                 | (6,336)                  |
| Non-compete agreements | 3 years               | 3,474                 | (1,632)                  | 3,474                 | (977)                    |

Edgar Filing: CHART INDUSTRIES INC - Form 10-Q

|                                     |          |            |             |            |             |
|-------------------------------------|----------|------------|-------------|------------|-------------|
| Customer relations                  | 13 years | 101,066    | (14,152)    | 101,066    | (8,647)     |
| Other                               |          | 60         | (21)        | 60         | (9)         |
|                                     |          | \$ 131,438 | \$ (27,176) | \$ 131,438 | \$ (18,875) |
| Indefinite-lived intangible assets: |          |            |             |            |             |
| Goodwill                            |          | \$ 247,049 |             | 247,144    |             |
| Trademarks and trade names          |          | 34,060     |             | 34,060     |             |
|                                     |          | \$ 281,109 |             | \$ 281,204 |             |

7

---

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
**(Dollars and shares in thousands, except per share amounts)**

**NOTE A Basis of Preparation Continued**

Amortization expense for finite-lived intangible assets was \$2,636 and \$4,290 for the three months ended September 30, 2007 and 2006, respectively, and \$8,304 and \$11,385 for the nine months ended September 30, 2007 and 2006, respectively. Amortization expense is estimated to be approximately \$10,900 for 2007 and \$9,800 for fiscal years 2008 through 2012.

*Employee Stock Options:* The Company adopted SFAS No. 123(R) Share-Based Payments, using the modified prospective method, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.

As of September 30, 2007 and 2006, there were 904 and 861 time-based options and 817 and 1,581 performance-based options outstanding under the Amended and Restated 2005 Stock Incentive Plan ( Stock Incentive Plan ), respectively. For the three months ended September 30, 2007 and 2006, the Company recorded \$441 and \$477, respectively, and \$1,965 and \$1,229 for the nine months ended September 30, 2007 and 2006, respectively, in compensation expense related to the time-based options. As of September 30, 2007, the total share-based compensation expected to be recognized over the weighted average period of approximately 3.7 years is \$3,112. On June 12, 2007, the Company completed its secondary stock offering in which First Reserve Fund X, L.P. achieved a return on its investment that caused 82% of the performance-based options to vest as specified in the Stock Incentive Plan. As a result of the vesting of the performance-based options, the Company recorded \$6,211 in stock-based compensation expense in the second quarter of 2007.

In August 2007, the Company granted 72 stock performance units with a weighted average grant date fair value of \$25.51. For the three and nine months ended September 30, 2007, the Company recorded \$154 in compensation expense related to the stock performance units. In May and July 2007, the Company granted restricted stock units covering 10 shares of common stock to non-employee directors. Each of the 6 grants has a fair market value of \$40 on the date of grant. In 2006, the Company granted restricted stock units covering 16 shares of common stock to non-employee directors. Each of the six grants of restricted stock units had a fair market value of \$40 on the date of grant. Restricted stock units for 4 and 3 shares were forfeited in the third and first quarters of 2007, respectively, upon the resignation of three directors. The remaining restricted stock units are expected to fully vest on the first anniversary of the date of grant or earlier in the event of a change in control as such term is defined in the Stock Incentive Plan. For the three and nine months ended September 30, 2007, the Company recorded \$63 and \$192, respectively, in director compensation expense related to the restricted stock units. For the three and nine months ended September 30, 2006, the Company recorded \$40 in director compensation related to the restricted stock units.

*Recently Issued Accounting Pronouncements:* In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, Fair Value Measurements (SFAS No. 157) which is effective for fiscal years beginning after November 15, 2007. SFAS No. 157 defines fair value to be applied to U.S. GAAP guidance requiring use of fair value, establishes a framework for measuring fair value and expands the disclosure requirements for fair value measurements. The Company is currently evaluating the impact of SFAS No. 157 on its financial position and results of operations.

In September 2006, the FASB issued SFAS No. 158, Employers Accounting for Defined Pension Benefit Plans and Other Postretirement Plans. This statement requires recognition on the balance sheet of the underfunded or overfunded status of pension and postretirement benefit plans. SFAS No. 158 also requires the recognition of changes in the funded status through other comprehensive income in the year that the changes occur. The amount of net periodic benefit cost recognized in an entity's results of operation will not change. SFAS No. 158 is effective for fiscal years ending after December 15, 2006. The requirement to measure plan assets and benefit obligations as of the date of the employer's fiscal year end balance sheet is effective for fiscal years ending after December 15, 2008. The Company adopted SFAS No. 158 as of December 31, 2006. The adoption of the statement had no effect on our financial position, results of operations, liquidity or cash flows.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities including an amendment of FASB Statement No. 115. SFAS No. 159 permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value, with unrealized gains and losses related to these financial instruments reported in earnings at each subsequent reporting date. This statement is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of SFAS No. 159 on its financial position and results of operations.

**NOTE B Debt and Credit Arrangements**

The Company has a senior secured credit facility (the Senior Credit Facility ) and \$170,000 of 7% senior subordinated notes (the Subordinated Notes ) outstanding. The Senior Credit Facility consists of a \$180,000 term loan facility (the Term Loan ) and a \$115,000 revolving credit facility (the Revolver ), of which \$55,000 may be used for letters of credit extending beyond one year from their date of issuance. The Term Loan matures on October 17, 2012 and the Revolver matures on October 17, 2010. The Term Loan does not require any principal payments prior to the maturity date. The interest rate under the Senior Credit Facility is, at the Company s option, the Alternative Base Rate ( ABR ) plus 1.0% or LIBOR plus 2.0% on the Term Loan and ABR plus 1.5% or LIBOR plus 2.5% on the Revolver. The

**Table of Contents****CHART INDUSTRIES, INC. AND SUBSIDIARIES****Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007****(Dollars and shares in thousands, except per share amounts)****NOTE B Debt and Credit Arrangements Continued**

applicable interest margin on the Revolver could decrease based upon the leverage ratio calculated at each fiscal quarter end. In addition, the Company is required to pay an annual administrative fee of \$100, a commitment fee of 0.5% on the unused Revolver balance, a letter of credit participation fee of 2.5% per annum on the letter of credit exposure and a letter of credit issuance fee of 0.25%. The obligations under the Senior Credit Facility are secured by substantially all of the assets of the Company and its U.S. subsidiaries and 65% of the capital stock of the Company's non-U.S. subsidiaries.

The Subordinated Notes are due in 2015 with interest payable semi-annually on April 15th and October 15th. The registration rights agreement required the Company to file an Exchange Offer Registration Statement and complete the exchange offer for the Subordinated Notes by August 14, 2006. Since the exchange offer was not completed when required, additional interest at a rate of 0.25% was incurred for the 90-day period commencing August 14, 2006, additional interest at a rate of 0.50% was incurred for the 90-day period commencing November 12, 2006 and additional interest at a rate of 0.75% was incurred for the 90-day period commencing February 10, 2007. The exchange offer was completed on April 6, 2007 and this additional interest ceased accruing as of that date. Any of the Subordinated Notes may be redeemed solely at the Company's option beginning on October 15, 2010. The initial redemption price is 104.563% of the principal amount, plus accrued interest. Also, any of the notes may be redeemed solely at the Company's option at any time prior to October 15, 2010, plus accrued interest and a make-whole premium. In addition, before October 15, 2008, up to 35% of the Subordinated Notes may be redeemed solely at the Company's option at a price of 109.125% of the principal amount, plus accrued interest, using the proceeds from the sales of certain kinds of capital stock. The Subordinated Notes are general unsecured obligations of the Company and are subordinated in right of payment to all existing and future senior debt of the Company, including the Senior Credit Facility, pari passu in right of payment with all future senior subordinated indebtedness of the Company, and senior in right of payment with any future indebtedness of the Company that expressly provides for its subordination to the Subordinated Notes. The Subordinated Notes are unconditionally guaranteed jointly and severally by substantially all of the Company's U.S. subsidiaries.

The Senior Credit Facility agreement and provisions of the indenture governing the Subordinated Notes contain a number of customary covenants, including but not limited to restrictions on the Company's ability to incur additional indebtedness, create liens or other encumbrances, sell assets, enter into sale and lease-back transactions, make certain payments, investments, loans, advances or guarantees, make acquisitions, engage in mergers or consolidations, pay dividends or distributions, and make capital expenditures. The Senior Credit Facility and indenture governing the Subordinated Notes also include financial covenants relating to leverage, interest coverage and fixed charge coverage ratios. The Company is in compliance with all covenants, including financial covenants. In June 2007, the Company made a \$40,000 voluntary principal payment under the Term Loan portion of the Senior Credit Facility primarily with proceeds from the exercise of the underwriters' over-allotment option in conjunction with the Company's secondary stock offering. As of September 30, 2007, there was \$80,000 outstanding under the Term Loan, \$170,000 outstanding under the Subordinated Notes and letters of credit and bank guarantees totaling \$32,681 supported by the Revolver.

Chart Ferox a.s. (Ferox), a wholly-owned subsidiary of the Company, maintains secured revolving credit facilities with borrowing capacity, including overdraft protection, of up to \$9,600, of which \$4,400 is available only for letters of credit and bank guarantees. Under the revolving credit facilities, Ferox may make borrowings in Czech Korunas, Euros and U.S. dollars. Borrowings in Koruna are at PRIBOR, borrowings in Euros are at EUROBOR and borrowings in U.S. dollars are at LIBOR, each with a fixed margin of 0.6 percent. Ferox is not required to pay a commitment fee to the lenders under the revolving credit facilities in respect to the unutilized commitments thereunder. Ferox must pay letter of credit and guarantee fees equal to 0.75% on the face amount of each guarantee. Ferox's land and buildings and accounts receivable secure \$4,600 and \$2,500, respectively, of the revolving credit facilities. As of September 30, 2007, there were no borrowings outstanding under the Ferox revolving credit facilities. However, there were \$1,479 of bank guarantees supported by the Ferox revolving credit facilities.





**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)

**NOTE C Earnings per Share**

The following table presents calculations of net income per share of common stock for the three and nine months ended September 30, 2007 and 2006:

|   | <b>Three Months Ended</b> |             | <b>Nine Months Ended</b> |             |
|---|---------------------------|-------------|--------------------------|-------------|
|   | <b>September 30</b>       |             | <b>September 30</b>      |             |
|   | <b>2007</b>               | <b>2006</b> | <b>2007</b>              | <b>2006</b> |
| Net income (1)  | \$ 12,112                 | \$ 6,932    | \$ 27,738                | \$ 18,286   |
| Net income per common share basic   | \$ 0.44                   | \$ 0.34     | \$ 1.05                  | \$ 1.45     |
| Net income per common share diluted   | \$ 0.42                   | \$ 0.34     | \$ 1.03                  | \$ 1.40     |
| Weighted average number of common shares outstanding basic                        | 27,671                    | 20,245      | 26,467                   | 12,579      |
| Incremental shares issuable upon assumed exercise of stock warrant                |                           |             |                          | 237         |
| Incremental shares issuable upon assumed conversion and exercise of stock options | 994                       | 153         | 554                      | 291         |
| Total shares diluted  | 28,665                    | 20,398      | 27,021                   | 13,107      |

(1) Net income for the nine months ended September 30, 2007 includes stock-based compensation of \$4,889 (\$7,086 before tax) primarily related to the vesting of the performance-based options in conjunction with the Company's secondary stock offering in June 2007.

**NOTE D Comprehensive Income (Loss)**

The components of accumulated other comprehensive income (loss) are as follows:

|   | <b>September<br/>30,<br/>2007</b> | <b>December<br/>31,<br/>2006</b> |
|---|-----------------------------------|----------------------------------|
| Foreign currency translation adjustments            | \$ 11,567                         | \$ 6,352                         |
| Minimum pension liability adjustments, net of taxes | 1,170                             | 1,170                            |

|    |        |    |       |
|----|--------|----|-------|
| \$ | 12,737 | \$ | 7,522 |
|----|--------|----|-------|

Comprehensive income for the three months ended September 30, 2007 and 2006 was \$17,943 and \$7,054, respectively. Comprehensive income for the nine months ended September 30, 2007 and 2006 was \$32,953 and \$21,630, respectively.

**NOTE E Employee Separation and Plant Closure Costs**

For the three and nine months ended September 30, 2007, the Company recorded employee separation and plant closure costs of \$135 and \$284, respectively, primarily related to the closure of the Distribution and Storage segment's idle Plaistow, New Hampshire facility. For the three and nine months ended September 30, 2006, the Company recorded employee separation and plant closure costs of \$73 and \$304, respectively, primarily related to the closure of the Distribution and Storage segment's idle Plaistow, New Hampshire facility.

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)

**NOTE E Employee Separation and Plant Closure Costs Continued**

The following table summarizes the Company's employee separation and plant closure costs activity for the three and nine months ended September 30, 2007 and 2006.

|   | <b>Three Months Ended September 30, 2007</b> |                                       |                   |              |
|---|--|---------------------------------------|-------------------|--------------|
|   | <b>Energy &amp;<br/>Chemicals</b>            | <b>Distribution<br/>&amp; Storage</b> | <b>BioMedical</b> | <b>Total</b> |
| One-time employee termination costs         | \$   | \$                                    | \$                | \$           |
| Other associated costs                      |  | 135                                   |                   | 135          |
| Employee separation and plant closure costs |  | 135                                   |                   | 135          |
| Reserve usage                               |  | (135)                                 | (7)               | (142)        |
| Change in reserve                           |  |                                       | (7)               | (7)          |
| Reserves as of July 1, 2007                 | 1,557  | 190                                   | 48                | 1,795        |
| Reserves as of September 30, 2007           | \$ 1,557                                     | \$ 190                                | \$ 41             | \$ 1,788     |

|   | <b>Nine Months Ended September 30, 2007</b> |                                       |                   |              |
|---|---|---------------------------------------|-------------------|--------------|
|   | <b>Energy &amp;<br/>Chemicals</b>           | <b>Distribution<br/>&amp; Storage</b> | <b>BioMedical</b> | <b>Total</b> |
| One-time employee termination costs         | \$  | \$                                    | \$                | \$           |
| Other associated costs                      |   | 284                                   |                   | 284          |
| Employee separation and plant closure costs |   | 284                                   |                   | 284          |
| Reserve usage                               |   | (284)                                 | (80)              | (364)        |
| Change in reserve                           |   |                                       | (80)              | (80)         |
| Reserves as of January 1, 2007              | 1,557                                       | 190                                   | 121               | 1,868        |
| Reserves as of September 30, 2007           | \$ 1,557                                    | \$ 190                                | \$ 41             | \$ 1,788     |

|   | <b>Three Months Ended September 30, 2006</b> |                                       |                   |              |
|---|--|---------------------------------------|-------------------|--------------|
|   | <b>Energy &amp;<br/>Chemicals</b>            | <b>Distribution<br/>&amp; Storage</b> | <b>BioMedical</b> | <b>Total</b> |
| One-time employee termination costs         | \$   | \$                                    | \$                | \$           |
| Other associated costs                      |  | 73                                    |                   | 73           |
| Employee separation and plant closure costs |  | 73                                    |                   | 73           |
| Reserve usage                               |  | (73)                                  | (5)               | (78)         |

|                                   |          |        |        |          |
|-----------------------------------|----------|--------|--------|----------|
| Change in reserve                 |          |        | (5)    | (5)      |
| Reserves as of July 1, 2006       | 1,557    | 190    | 137    | 1,884    |
| Reserves as of September 30, 2006 | \$ 1,557 | \$ 190 | \$ 132 | \$ 1,879 |

**Nine Months Ended September 30, 2006**

|   | <b>Energy &amp;<br/>Chemicals</b> | <b>Distribution<br/>&amp; Storage</b> | <b>BioMedical</b> | <b>Total</b> |
|---|-----------------------------------|---------------------------------------|-------------------|--------------|
| One-time employee termination costs         | \$                                | \$                                    | \$                | \$           |
| Other associated costs                      | 9                                 | 295                                   |                   | 304          |
| Employee separation and plant closure costs | 9                                 | 295                                   |                   | 304          |
| Reserve usage                               | (9)                               | (295)                                 | (107)             | (411)        |
| Change in reserve                           |                                   |                                       | (107)             | (107)        |
| Reserves as of January 1, 2006              | 1,557                             | 190                                   | 239               | 1,986        |
| Reserves as of September 30, 2006           | \$ 1,557                          | \$ 190                                | \$ 132            | \$ 1,879     |

The employee separation and plant closure costs reserve of \$1,788 and \$1,879 at September 30, 2007 and 2006, respectively, were for one-time employee termination costs.

**Table of Contents****CHART INDUSTRIES, INC. AND SUBSIDIARIES****Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007****(Dollars and shares in thousands, except per share amounts)****NOTE F Acquisitions**

On May 26, 2006, the Company acquired the common stock of Cooler Service Company, Inc. ( CSC ) based in Tulsa, Oklahoma. The consideration paid was \$15,927, net of cash acquired, including transaction costs. The acquisition was funded with cash on hand. The estimated fair value of the net assets acquired and goodwill at the date of acquisition was \$8,050 and \$8,654, respectively. CSC designs and manufactures air cooled heat exchangers for multiple markets, including hydrocarbon, petrochemical and industrial gas processing, and power generation. CSC has been included in the Company's Energy and Chemicals segment.

On March 2, 2007, the Company purchased the remaining minority interest in Chart Ferox a.s for a purchase price of \$1,612. The purchase price was applied to eliminate the minority interest in Ferox a.s. of approximately \$2,000. The difference between the purchase price and the value of the minority interest eliminated was allocated to adjust the fair value of the assets originally acquired.

**NOTE G Assets Held for Sale**

The Company has entered into an agreement to sell the idle building and a portion of the land at its Plaistow, New Hampshire facility. The Company sold the building in November 2007. The Plaistow facility is classified as assets held for sale on the Company's unaudited condensed consolidated balance sheet as of September 30, 2007 and the audited consolidated balance sheet as of December 31, 2006 based on the carrying value of \$3,084.

**NOTE H Income Taxes**

The Company adopted the provisions of FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* ( FIN 48 ) on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with SFAS No. 5, *Accounting for Contingencies*. As required by FIN 48, which clarifies SFAS No. 109, *Accounting for Income Taxes*, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At the adoption date, the Company applied FIN 48 to all tax positions for which the statute of limitations remained open. As a result of the implementation of FIN 48, the Company did not recognize material adjustments in the liability for unrecognized tax benefits. The amount of unrecognized tax benefits as of January 1, 2007 was \$3,900. This amount includes \$1,100 of unrecognized tax benefits which, if ultimately recognized, will reduce the Company's annual effective tax rate. There have been no material changes in unrecognized tax benefits since January 1, 2007.

The Company is subject to income taxes in the U.S. federal jurisdiction, and various states and foreign jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Company is no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by tax authorities for years prior to 2003.

The Internal Revenue Service ( IRS ) commenced an examination of the Company's U.S. income tax returns for 2004 and 2005 in January 2007. The Company expects the examination to be concluded and settled during 2008. The Company is also currently under examination by a number of state tax authorities. The Company also expects those examinations to be concluded and settled during 2008. It is reasonably possible that a change in the unrecognized tax benefits may occur, however, quantification of an estimated range cannot be made at this time.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company had accrued approximately \$302 for the payment of interest and penalties at January 1, 2007 which is included in the unrecognized tax benefits above. During the nine months ended September 30, 2007, the Company accrued approximately \$150 in additional interest associated with uncertain tax positions. The Company had \$452 in interest and penalties accrued at September 30, 2007.

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)

**NOTE I Employee Benefit Plans**

The Company has four defined benefit pension plans covering certain U.S. hourly and salary employees. All of these plans were frozen as of February 28, 2006. The defined benefit plans provide benefits based primarily on the participants' years of service and compensation.

The following table sets forth the components of net periodic pension benefit for the three and nine months ended September 30, 2007 and 2006.

|                                | <b>Three Months Ended</b> |             | <b>Nine Months Ended</b> |             |
|--------------------------------|---------------------------|-------------|--------------------------|-------------|
|                                | <b>September 30,</b>      |             | <b>September 30,</b>     |             |
|                                | <b>2007</b>               | <b>2006</b> | <b>2007</b>              | <b>2006</b> |
| Interest cost                  | 523                       | 510         | 1,569                    | 1,530       |
| Expected return on plan assets | (680)                     | (618)       | (2,040)                  | (1,854)     |
| Recognized actuarial gain      |                           |             |                          |             |
| Total pension benefit          | \$(157)                   | \$(108)     | \$ (471)                 | \$ (324)    |

**NOTE J Reporting Segments**

The structure of the Company's internal organization is divided into the following three reportable segments: Energy and Chemicals ( E&C ), Distribution and Storage ( D&S ) and BioMedical. The Company's reportable segments are business units that offer different products and are each managed separately because they manufacture and distribute distinct products with different production processes and sales and marketing approaches. The E&C segment sells brazed aluminum and air-cooled heat exchangers, cold boxes and liquefied natural gas vacuum-insulated pipe to natural gas, petrochemical processing and industrial gas companies who use them for the liquefaction and separation of natural and industrial gases. The D&S segment sells cryogenic bulk storage systems, cryogenic packaged gas systems, cryogenic systems and components, beverage liquid CO<sub>2</sub> systems and cryogenic services to various companies for the storage and transportation of both industrial and natural gases. The BioMedical segment sells medical respiratory products, biological storage systems, other oxygen products and magnetic resonance imaging cryostat components. Due to the nature of the products that each segment sells, there are no intersegment sales. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and stock-based compensation expenses that are not allocated to the reporting segments.

The Company evaluates performance and allocates resources based on operating income or loss before gain on sale of assets, net interest expense, financing costs amortization expense, foreign currency gain or loss, income taxes and minority interest. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

Information for the Company's three reportable segments and its corporate headquarters is presented below:

|                         | <b>Three Months Ended September 30, 2007</b> |                                     |                   |                  | <b>Total</b> |
|-------------------------|--|-------------------------------------|-------------------|------------------|--------------|
|                         | <b>Energy<br/>and<br/>Chemicals</b>          | <b>Distribution<br/>and Storage</b> | <b>BioMedical</b> | <b>Corporate</b> |              |
| Sales                   | \$ 58,396                                    | \$ 85,106                           | \$ 20,168         | \$               | \$ 163,670   |
| Operating income (loss) | 7,392  | 16,627                              | 2,964             | (5,569)          | 21,414       |

|  | <b>Nine Months Ended September 30, 2007</b> |                                     |                   |                  |              |
|--|---|-------------------------------------|-------------------|------------------|--------------|
|  | <b>Energy<br/>and<br/>Chemicals</b>         | <b>Distribution<br/>and Storage</b> | <b>BioMedical</b> | <b>Corporate</b> | <b>Total</b> |
| Sales                                  | \$ 168,765                                  | \$ 248,447                          | \$ 66,508         | \$               | \$ 483,720   |
| Operating income (loss) <sup>(1)</sup> | 17,260                                      | 53,817                              | 12,721            | (25,348)         | 58,450       |

---



**Table of Contents****CHART INDUSTRIES, INC. AND SUBSIDIARIES****Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007****(Dollars and shares in thousands, except per share amounts)****NOTE J Reporting Segments Continued**

|                         | <b>Three Months Ended September 30, 2006</b> |                                     |                   |                  |              |
|-------------------------|--|-------------------------------------|-------------------|------------------|--------------|
|                         | <b>Energy<br/>and<br/>Chemicals</b>          | <b>Distribution<br/>and Storage</b> | <b>BioMedical</b> | <b>Corporate</b> | <b>Total</b> |
| Sales                   | \$ 54,411                                    | \$ 67,953                           | \$20,461          | \$               | \$142,825    |
| Operating income (loss) | 5,462  | 13,491                              | 4,365             | (6,449)          | 16,869       |
|                         | <b>Nine Months Ended September 30, 2006</b>  |                                     |                   |                  |              |
|                         | <b>Energy<br/>and<br/>Chemicals</b>          | <b>Distribution<br/>and Storage</b> | <b>BioMedical</b> | <b>Corporate</b> | <b>Total</b> |
| Sales                   | \$138,075                                    | \$194,783                           | \$60,174          | \$               | \$393,032    |
| Operating income (loss) | 11,738                                       | 39,605                              | 12,855            | (16,719)         | 47,479       |

- (1) The operating loss for Corporate for the nine months ended September 30, 2007 includes stock-based compensation of \$7,086 primarily related to the vesting of the performance-based options in conjunction with the Company's secondary stock offering in June 2007. In addition, the operating loss for Corporate for the nine months ended September 30, 2007 includes \$777 of secondary stock offering expenses.

**NOTE K Supplemental Guarantor Financial Information**

The Company's Subordinated Notes issued in October 2005 are guaranteed on a full, unconditional and joint and several basis by the following wholly owned subsidiaries: Chart Inc., CAIRE Inc., Chart Energy and Chemicals, Inc., Chart Cooler Service Company, Inc., Chart International Holdings, Inc., Chart Asia Inc. and Chart International Inc. The following subsidiaries are not guarantors of the notes:

**Non-Guarantor Subsidiaries**

|  | <b>Jurisdiction</b> |
|--|---------------------|
| Changzhou CEM Cryo Equipment Co., Ltd.                                   | China               |
| Chart Australia Pty. Ltd.  | Australia           |
| Chart Biomedical Limited   | United Kingdom      |
| Chart Cryogenic Distribution Equipment (Changzhou) Co., Ltd. (50% owned) | China               |
| Chart Cryogenic Engineering Systems (Changzhou) Co., Ltd.                | China               |
| Chart Cryogenic Equipment (Changzhou) Co., Ltd.                          | China               |
| Chart Ferox a.s.   | Czech Republic      |
| Chart Ferox GmbH   | Germany             |
| GTC of Clarksville, LLC  | Delaware            |
| Lox Taiwan (16% owned)   | Taiwan              |
| Zhangjigang Chart Hailu Cryogenic Equipment Co., Ltd.                    | China               |

The following supplemental condensed consolidating and combining financial information of the Issuer, Subsidiary Guarantors and Subsidiary Non-Guarantors presents statements of operations for the three and nine months ended September 30, 2007 and 2006, balance sheets as of September 30, 2007 and December 31, 2006 and statements of cash flows for the nine months ended September 30, 2007 and 2006.

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING BALANCE SHEET**  
As of September 30, 2007

|  | Issuer     | Subsidiary<br>Guarantors | Subsidiary<br>Non-<br>Guarantors | Consolidating<br>Adjustments | Total      |
|--|------------|--------------------------|----------------------------------|------------------------------|------------|
| <b>ASSETS</b>                              |            |                          |                                  |                              |            |
| Cash and cash equivalents                  | \$ 32,002  | \$ 755                   | \$ 29,669                        | \$                           | \$ 62,426  |
| Accounts receivable, net                   |            | 59,917                   | 19,147                           |                              | 79,064     |
| Inventory, net                             |            | 48,433                   | 36,055                           | (467)                        | 84,021     |
| Other current assets                       | 7,464      | 31,177                   | 13,523                           |                              | 52,164     |
| Total current assets                       | 39,466     | 140,282                  | 98,394                           | (467)                        | 277,675    |
| Property, plant and equipment, net         |            | 62,092                   | 34,497                           |                              | 96,589     |
| Goodwill                                   |            | 189,562                  | 57,487                           |                              | 247,049    |
| Intangible assets, net                     |            | 136,283                  | 2,039                            |                              | 138,322    |
| Investments in affiliates                  | 145,546    | 53,223                   |                                  | (198,769)                    |            |
| Intercompany receivables                   | 401,172    |                          |                                  | (401,172)                    |            |
| Other assets                               | 10,198     | 1,688                    | 1,201                            |                              | 13,087     |
| Total assets                               | \$ 596,382 | \$ 583,130               | \$ 193,618                       | \$ (600,408)                 | \$ 772,722 |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b> |            |                          |                                  |                              |            |
| Accounts payable and accruals              | \$ (9,281) | \$ 129,397               | \$ 26,298                        | \$ (91)                      | \$ 146,323 |
| Total current liabilities                  | (9,281)    | 129,397                  | 26,298                           | (91)                         | 146,323    |
| Long-term debt                             | 250,000    |                          |                                  |                              | 250,000    |
| Intercompany payables                      |            | 295,188                  | 106,360                          | (401,548)                    |            |
| Other long-term liabilities                | 49,917     | 12,999                   | 7,737                            |                              | 70,653     |
| Total liabilities                          | 290,636    | 437,584                  | 140,395                          | (401,639)                    | 466,976    |
| Common stock                               | 280        |                          |                                  |                              | 280        |
| Other stockholders equity                  | 305,466    | 145,546                  | 53,223                           | (198,769)                    | 305,466    |
| Total stockholders equity                  | 305,746    | 145,546                  | 53,223                           | (198,769)                    | 305,746    |
| Total liabilities and stockholders equity  | \$ 596,382 | \$ 583,130               | \$ 193,618                       | \$ (600,408)                 | \$ 772,722 |

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING BALANCE SHEET (AUDITED)**  
As of December 31, 2006

|  | Issuer      | Subsidiary<br>Guarantors | Subsidiary<br>Non-<br>Guarantors | Consolidating<br>Adjustments | Total      |
|--|-------------|--------------------------|----------------------------------|------------------------------|------------|
| <b>ASSETS</b>                              |             |                          |                                  |                              |            |
| Cash and cash equivalents                  | \$ 6,084    | \$ 114                   | \$ 12,656                        | \$                           | \$ 18,854  |
| Accounts receivable, net                   |             | 58,320                   | 18,442                           |                              | 76,762     |
| Inventory, net                             |             | 43,559                   | 29,508                           | (210)                        | 72,857     |
| Other current assets                       | 8,319       | 39,955                   | 13,888                           |                              | 62,162     |
| Total current assets                       | 14,403      | 141,948                  | 74,494                           | (210)                        | 230,635    |
| Property, plant and equipment, net         |             | 57,469                   | 28,254                           |                              | 85,723     |
| Goodwill                                   |             | 189,671                  | 57,473                           |                              | 247,144    |
| Intangible assets, net                     |             | 143,998                  | 2,625                            |                              | 146,623    |
| Investments in affiliates                  | 104,109     | 38,326                   |                                  | (142,435)                    |            |
| Intercompany receivables                   | 421,549     |                          |                                  | (421,549)                    |            |
| Other assets                               | 11,126      | 1,580                    | 2,044                            |                              | 14,750     |
| Total assets                               | \$ 551,187  | \$ 572,992               | \$ 164,890                       | \$ (564,194)                 | \$ 724,875 |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b> |             |                          |                                  |                              |            |
| Accounts payable and accruals              | \$ (11,935) | \$ 122,734               | \$ 28,908                        | \$ (466)                     | \$ 139,241 |
| Total current liabilities                  | (11,935)    | 122,734                  | 28,908                           | (466)                        | 139,241    |
| Long-term debt                             | 290,000     |                          |                                  |                              | 290,000    |
| Intercompany payables                      |             | 332,535                  | 88,758                           | (421,293)                    |            |
| Other long-term liabilities                | 53,388      | 13,614                   | 8,898                            |                              | 75,900     |
| Total liabilities                          | 331,453     | 468,883                  | 126,564                          | (421,759)                    | 505,141    |
| Common stock                               | 256         |                          |                                  |                              | 256        |
| Other stockholders equity                  | 219,478     | 104,109                  | 38,326                           | (142,435)                    | 219,478    |
| Total stockholders equity                  | 219,734     | 104,109                  | 38,326                           | (142,435)                    | 219,734    |
| Total liabilities and stockholders equity  | \$ 551,187  | \$ 572,992               | \$ 164,890                       | \$ (564,194)                 | \$ 724,875 |

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS**  
**For the Three Months Ended September 30, 2007**

|  | <b>Issuer</b> | <b>Subsidiary<br/>Guarantors</b> | <b>Subsidiary<br/>Non-<br/>Guarantors</b> | <b>Consolidating<br/>Adjustments</b> | <b>Total</b> |
|--|---------------|----------------------------------|---|--------------------------------------|--------------|
| Net sales  | \$            | \$ 121,319                       | \$ 45,206                                 | \$ (2,855)                           | \$ 163,670   |
| Cost of sales  |               | 87,973                           | 33,356                                    | (3,049)                              | 118,280      |
| Gross profit   |               | 33,346                           | 11,850                                    | 194                                  | 45,390       |
| Selling, general and administrative expenses                                 | 275           | 20,160                           | 3,541                                     |                                      | 23,976       |
| Operating income   | (275)         | 13,186                           | 8,309                                     | 194                                  | 21,414       |
| Interest expense   | 5,643         | (21)                             | (104)                                     |                                      | 5,518        |
| Other (income) expense, net  |               | (47)                             | (463)                                     |                                      | (510)        |
| Minority interest, net of tax  |               |                                  | (18)                                      |                                      | (18)         |
| Income (loss) before income taxes and equity in net (income) of subsidiaries | (5,918)       | 13,254                           | 8,894                                     | 194                                  | 16,424       |
| Income tax (benefit) provision   | (1,309)       | 5,000                            | 621                                       |                                      | 4,312        |
| Equity in net (income) of subsidiaries                                       | (16,721)      | (8,467)                          |   | 25,188                               |              |
| Net income   | \$ 12,112     | \$ 16,721                        | \$ 8,273                                  | \$ (24,994)                          | \$ 12,112    |

**CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS**  
**For the Three Months Ended September 30, 2006**

|  | <b>Issuer</b> | <b>Subsidiary<br/>Guarantors</b> | <b>Subsidiary<br/>Non-<br/>Guarantors</b> | <b>Consolidating<br/>Adjustments</b> | <b>Total</b> |
|--|---------------|----------------------------------|---|--------------------------------------|--------------|
| Net sales                                    | \$            | \$ 110,973                       | \$ 32,923                                 | \$ (1,071)                           | \$ 142,825   |
| Cost of sales                                |               | 81,241                           | 23,220                                    | (1,076)                              | 103,385      |
| Gross profit                                 |               | 29,732                           | 9,703                                     | 5                                    | 39,440       |
| Selling, general and administrative expenses | 424           | 19,189                           | 2,958                                     |                                      | 22,571       |
| Operating (loss) income                      | (424)         | 10,543                           | 6,745                                     | 5                                    | 16,869       |
| Interest expense                             | 6,169         | (23)                             | (21)                                      |                                      | 6,125        |
| Other (income) expense, net                  | 393           | 59                               | (85)                                      |                                      | 367          |
| Minority interest, net of tax                |               |                                  | 73  |                                      | 73           |
|  | (6,986)       | 10,507                           | 6,778                                     | 5                                    | 10,304       |

Edgar Filing: CHART INDUSTRIES INC - Form 10-Q

|  |          |           |          |             |          |
|--|----------|-----------|----------|-------------|----------|
| Income (loss) before income taxes<br>and equity in net (income) of<br>subsidiaries |          |           |          |             |          |
| Income tax provision (benefit)   | (2,284)  | 4,968     | 688      |             | 3,372    |
| Equity in net (income) of<br>subsidiaries  | (11,634) | (6,095)   |          | 17,729      |          |
| Net income   | \$ 6,932 | \$ 11,634 | \$ 6,090 | \$ (17,724) | \$ 6,932 |

17

---

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS**  
**For the Nine Months Ended September 30, 2007**

|  | <b>Issuer</b> | <b>Subsidiary<br/>Guarantors</b> | <b>Subsidiary<br/>Non-<br/>Guarantors</b> | <b>Consolidating<br/>Adjustments</b> | <b>Total</b> |
|--|---------------|----------------------------------|---|--------------------------------------|--------------|
| Net sales  | \$            | \$ 355,285                       | \$ 133,591                                | \$ (5,156)                           | \$ 483,720   |
| Cost of sales  |               | 252,561                          | 99,741                                    | (5,089)                              | 347,213      |
| Gross profit   |               | 102,724                          | 33,850                                    | (67)                                 | 136,507      |
| Selling, general and administrative expenses                                 | 1,027         | 67,973                           | 9,057                                     |                                      | 78,057       |
| Operating income   | (1,027)       | 34,751                           | 24,793                                    | (67)                                 | 58,450       |
| Interest expense   | 18,830        | 28                               | (216)                                     |                                      | 18,642       |
| Other (income) expense, net  |               |                                  | (221)                                     |                                      | (221)        |
| Minority interest, net   |               |                                  | (77)                                      |                                      | (77)         |
| Income (loss) before income taxes and equity in net (income) of subsidiaries | (19,857)      | 34,723                           | 25,307                                    | (67)                                 | 40,106       |
| Income tax (benefit) provision   | (6,061)       | 15,292                           | 3,137                                     |                                      | 12,368       |
| Equity in net (income) of subsidiaries                                       | (41,534)      | (22,103)                         |   | 63,637                               |              |
| Net income   | \$ 27,738     | \$ 41,534                        | \$ 22,170                                 | \$ (63,704)                          | \$ 27,738    |

**CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS**  
**For the Nine Months Ended September 30, 2006**

|  | <b>Issuer</b> | <b>Subsidiary<br/>Guarantors</b> | <b>Subsidiary<br/>Non-<br/>Guarantors</b> | <b>Consolidating<br/>Adjustments</b> | <b>Total</b> |
|--|---------------|----------------------------------|---|--------------------------------------|--------------|
| Net sales                                    | \$            | \$ 302,539                       | \$ 93,386                                 | \$ (2,893)                           | \$ 393,032   |
| Cost of sales                                |               | 217,500                          | 65,771                                    | (2,779)                              | 280,492      |
| Gross profit                                 |               | 85,039                           | 27,615                                    | (114)                                | 112,540      |
| Selling, general and administrative expenses | 1,023         | 56,917                           | 7,112                                     | 9                                    | 65,061       |
| Operating income                             | (1,023)       | 28,122                           | 20,503                                    | (123)                                | 47,479       |
| Interest expense                             | 19,403        | (53)                             | (94)                                      |                                      | 19,256       |
| Other (income) expense, net                  | 1,132         | 160                              | (337)                                     |                                      | 955          |
| Minority interest, net of tax                |               |                                  | 120                                       |                                      | 120          |
|  | (21,558)      | 28,015                           | 20,814                                    | (123)                                | 27,148       |

Edgar Filing: CHART INDUSTRIES INC - Form 10-Q

|  |           |           |           |             |           |
|--|-----------|-----------|-----------|-------------|-----------|
| Income (loss) before income taxes<br>and equity in net (income) of<br>subsidiaries |           |           |           |             |           |
| Income tax provision (benefit)   | (7,020)   | 13,150    | 2,732     |             | 8,862     |
| Equity in net (income) of<br>subsidiaries  | (32,824)  | (17,959)  |           | 50,783      |           |
| Net income   | \$ 18,286 | \$ 32,824 | \$ 18,082 | \$ (50,906) | \$ 18,286 |

18

---



**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS**  
**For the Nine Months Ended September 30, 2007**

|   | <b>Issuer</b> | <b>Subsidiary<br/>Guarantors</b> | <b>Subsidiary<br/>Non<br/>Guarantors</b> | <b>Consolidating<br/>Adjustments</b> | <b>Total</b> |
|---|---------------|----------------------------------|--|--------------------------------------|--------------|
| Cash flows from operating activities:               |               |                                  |  |                                      |              |
| Net cash (used in) provided by operating activities | \$ (15,053)   | \$ 51,828                        | \$ 15,557                                | \$ 1,826                             | \$ 54,158    |
| Cash flows from investing activities:               |               |                                  |  |                                      |              |
| Capital expenditures                                |               | (8,639)                          | (6,936)                                  |                                      | (15,575)     |
| Acquisition of minority interest and other assets   |               |                                  | (1,612)                                  |                                      | (1,612)      |
| Net cash (used in) investing activities             |               | (8,639)                          | (8,548)                                  |                                      | (17,187)     |
| Cash flows from financing activities:               |               |                                  |  |                                      |              |
| Net change in debt                                  | (40,000)      | (750)                            |  |                                      | (40,750)     |
| Proceeds from secondary stock offering, net         | 38,292        |                                  |  |                                      | 38,292       |
| Other financing activities                          | 5,948         |                                  | 1,328                                    |                                      | 7,276        |
| Intercompany account changes                        | 36,731        | (41,798)                         | 6,893                                    | (1,826)                              |              |
| Net cash provided by (used in) financing activities | 40,971        | (42,548)                         | 8,221                                    | (1,826)                              | 4,818        |
| Net increase in cash and cash equivalents           | 25,918        | 641                              | 15,230                                   |                                      | 41,789       |
| Effect of exchange rate changes                     |               |                                  | 1,783                                    |                                      | 1,783        |
| Cash and cash equivalents, beginning of period      | 6,084         | 114                              | 12,656                                   |                                      | 18,854       |
| Cash and cash equivalents, end of period            | \$ 32,002     | \$ 755                           | \$ 29,669                                | \$                                   | \$ 62,426    |

**Table of Contents**

**CHART INDUSTRIES, INC. AND SUBSIDIARIES**  
**Notes to Unaudited Condensed Consolidated Financial Statements September 30, 2007**  
(Dollars and shares in thousands, except per share amounts)  
**CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS**  
**For the Nine Months Ended September 30, 2006**

|  | Issuer      | Subsidiary<br>Guarantors | Subsidiary<br>Non<br>Guarantors | Consolidating<br>Adjustments | Total     |
|--|-------------|--------------------------|---------------------------------|------------------------------|-----------|
| Cash flows from operating activities:                |             |                          |                                 |                              |           |
| Net cash (used in) provided by operating activities  | \$ (21,405) | \$ 38,288                | \$ 13,882                       | \$ 2,724                     | \$ 33,489 |
| Cash flows from investing activities:                |             |                          |                                 |                              |           |
| Capital expenditures                                 |             | (10,616)                 | (2,863)                         |                              | (13,479)  |
| Acquisition of business, net of cash                 |             | (15,858)                 |                                 |                              | (15,858)  |
| Other investing activities                           | (138)       | 716                      | (609)                           |                              | (31)      |
| Net cash (used in) investing activities              | (138)       | (25,758)                 | (3,472)                         |                              | (29,368)  |
| Cash flows from financing activities:                |             |                          |                                 |                              |           |
| Net change in debt                                   | (55,000)    |                          | (2,354)                         |                              | (57,354)  |
| Proceeds from sale of stock                          | 172,512     |                          |                                 |                              | 172,512   |
| Cash dividend  | (150,313)   |                          |                                 |                              | (150,313) |
| Proceeds from warrant and option exercises           | 39,237      |                          |                                 |                              | 39,237    |
| Payment of deferred financing costs                  | (854)       |                          |                                 |                              | (854)     |
| Intercompany account changes                         | 14,864      | (12,294)                 | 154                             | (2,724)                      |           |
| Net cash provided by (used in) financing activities  | 20,446      | (12,294)                 | (2,200)                         | (2,724)                      | 3,228     |
| Net (decrease) increase in cash and cash equivalents | (1,097)     | 236                      | 8,210                           |                              | 7,349     |
| Effect of exchange rate changes                      |             | 10                       | 92                              |                              | 102       |
| Cash and cash equivalents, beginning of period       | 7,191       | 272                      | 3,863                           |                              | 11,326    |
| Cash and cash equivalents, end of period             | \$ 6,094    | \$ 518                   | \$ 12,165                       | \$                           | \$ 18,777 |

**Table of Contents**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

**Overview**

Chart Industries, Inc. (the Company, Chart, or we) is a leading independent global manufacturer of highly engineered equipment used in the production, storage and end-use of hydrocarbon and industrial gases. We supply engineered equipment used throughout the global liquid supply chain. The largest portion of end-use applications for our products is energy-related. We are a leading manufacturer of standard and engineered equipment primarily used for low temperature and cryogenic applications. We have developed an expertise in cryogenic systems and equipment, which operate at low temperatures sometimes approaching absolute zero (0 kelvin; -273° Centigrade; - 459° Fahrenheit). The majority of our products, including vacuum-insulated containment vessels, heat exchangers, cold boxes and other cryogenic components are used throughout the liquid gas supply chain for the purification, liquefaction, distribution, storage and end-use of hydrocarbon and industrial gases.

For the nine months ended September 30, 2007, orders have remained strong at \$593.7 million and backlog has increased to \$426.1 million compared to \$319.2 million at December 31, 2006. This increase is primarily due to increased demand in the global hydrocarbon processing and industrial gas markets served by our Energy and Chemicals ( E&C ) and Distribution and Storage ( D&S ) segments and continued penetration of the international markets served by our BioMedical segment. Also, we experienced growth in our sales, gross profit and operating income for the nine months ended September 30, 2007 compared to the same period in 2006, which was primarily attributable to higher volume across all of our business segments, and the timing of product price increases, particularly in our D&S segment. Sales for the nine months ended September 30, 2007 were \$483.7 million compared to sales of \$393.0 million for the nine months ended September 30, 2006, reflecting an increase of \$90.7 million, or 23.1%. Our gross profit for the nine months ended September 30, 2007 was \$136.5 million, or 28.2% of sales, as compared to \$112.5 million, or 28.6% of sales, for the same period in 2006. In addition, our operating income for the nine months ended September 30, 2007 was \$58.5 million compared to \$47.5 million for the same period in 2006. The slight difference in our gross profit margin was primarily attributed to our BioMedical segment as the margins in our D&S and E&C segments remained relatively constant.

As a result of the continued growth in many of the markets we serve, higher product pricing, our present and anticipated customer order trends and our backlog level of \$426.1 million as of September 30, 2007, we presently expect to experience continued sales and operating income growth for the remaining three months of 2007 as compared to the same period in 2006. However, we expect a slow down in U.S. bulk storage system orders to continue into 2008. We also believe that our cash flow from operations, available cash and available borrowings under the senior secured credit facility should be adequate to meet our working capital, capital expenditure, debt service and other funding requirements for the remaining three months of 2007.

**Table of Contents****Results of Operations for the Three Months Ended September 30, 2007 and 2006**

The following table sets forth sales, gross profit, gross profit margin and operating income or loss for our three operating segments for the three and nine months ended September 30, 2007 and 2006:

|                                | Three Months Ended<br>September 30, |            | Nine Months Ended<br>September 30, |            |
|--------------------------------|-------------------------------------|------------|------------------------------------|------------|
|                                | 2007                                | 2006       | 2007                               | 2006       |
| <b>Sales</b>                   |                                     |            |                                    |            |
| Energy & Chemicals             | \$ 58,396                           | \$ 54,411  | \$ 168,765                         | \$ 138,075 |
| Distribution & Storage         | 85,106                              | 67,953     | 248,447                            | 194,783    |
| BioMedical                     | 20,168                              | 20,461     | 66,508                             | 60,174     |
| Total                          | \$ 163,670                          | \$ 142,825 | \$ 483,720                         | \$ 393,032 |
| <b>Gross Profit</b>            |                                     |            |                                    |            |
| Energy & Chemicals             | \$ 13,087                           | \$ 10,222  | \$ 34,931                          | \$ 28,083  |
| Distribution & Storage         | 26,221                              | 21,813     | 79,497                             | 62,791     |
| BioMedical                     | 6,082                               | 7,405      | 22,079                             | 21,666     |
| Total                          | \$ 45,390                           | \$ 39,440  | \$ 136,507                         | \$ 112,540 |
| <b>Gross Profit Margin</b>     |                                     |            |                                    |            |
| Energy & Chemicals             | 22.4%                               | 18.8%      | 20.7%                              | 20.3%      |
| Distribution & Storage         | 30.8%                               | 32.1%      | 32.0%                              | 32.2%      |
| BioMedical                     | 30.2%                               | 36.2%      | 33.2%                              | 36.0%      |
| Total                          | 27.7%                               | 27.6%      | 28.2%                              | 28.6%      |
| <b>Operating Income (Loss)</b> |                                     |            |                                    |            |
| Energy & Chemicals             | \$ 7,392                            | \$ 5,462   | \$ 17,260                          | \$ 11,738  |
| Distribution & Storage         | 16,627                              | 13,491     | 53,817                             | 39,605     |
| BioMedical                     | 2,964                               | 4,365      | 12,721                             | 12,855     |
| Corporate                      | (5,569)                             | (6,449)    | (25,348)                           | (16,719)   |
| Total                          | \$ 21,414                           | \$ 16,869  | \$ 58,450                          | \$ 47,479  |

**Sales**

Sales for the three months ended September 30, 2007 were \$163.7 million compared to \$142.8 million for the three months ended September 30, 2006, reflecting an increase of \$20.9 million, or 14.6%. E&C segment sales were \$58.4 million for the three months ended September 30, 2007 compared with sales of \$54.4 million for three months ended September 30, 2006, which reflected an increase of \$4.0 million or 7.4%. This increase in sales resulted primarily from higher volume for brazed aluminum heat exchangers. D&S segment sales increased \$17.1 million, or 25.3%, to \$85.1 million for the three months ended September 30, 2007 from \$68.0 million for the three months ended September 30, 2006. Sales of bulk storage systems and packaged gas systems increased \$12.5 million and \$4.6 million, respectively, for the three months ended September 30, 2007 compared to the same period in 2006. These increases were primarily due to higher volume as a result of continued growth in the global industrial gas market, and price increases to absorb escalating raw material costs. Another contributing factor to the increased D&S sales in the third quarter of 2007 compared with the same period in 2006 was favorable foreign currency translation of

approximately \$1.3 million as a result of the weakened U.S. dollar compared to the Euro and Czech Koruna. BioMedical segment sales for the three months ended September 30, 2007 were \$20.2 million compared to \$20.5 million for the same period in 2006, which reflected a decrease of \$0.3 million. Biological storage system sales increased \$1.4 million primarily due to higher volume in international markets. The increase was offset by a decrease in U.S. medical respiratory product sales of \$1.7 million due to a change in U.S. government reimbursement for liquid oxygen therapy systems. It is expected that the unfavorable reimbursement programs will continue into 2008 which will continue to hamper growth of our U.S. medical respiratory product sales.

**Table of Contents*****Gross Profit and Margin***

Gross profit for the three months ended September 30, 2007 was \$45.4 million, or 27.7% of sales, versus \$39.4 million, or 27.6% of sales, for the three months ended September 30, 2006 and reflected an increase of \$6.0 million. E&C segment gross profit increased \$2.9 million and its margin increased 3.6 percentage points, respectively, primarily due to a favorable change in project mix for process systems. The improvement in gross profit is also due to higher sales volume in brazed aluminum heat exchangers. These improvements were partially offset by increased manufacturing costs due to lower productivity for air-cooled heat exchangers. Gross profit for the D&S segment increased \$4.4 million, while the margin declined 1.3 percentage points, in the 2007 three month period compared to the 2006 three month period. The increase in gross profit is due to higher sales volume and to a lesser extent the timing of product price increases in both bulk storage and packaged gas systems to absorb escalating raw material costs. The decrease in the D&S segment margin was caused by a change in sales mix within bulk storage systems product lines and increased raw material surcharges. BioMedical gross profit decreased \$1.3 million due to lower sales volume for medical respiratory products partially offset by higher sales volume for biological storage systems in international markets. The margin decreased 6.0 percentage points in the 2007 period compared to the 2006 period due to higher raw material and warranty costs.

***Selling, General and Administrative Expenses ( SG&A )***

SG&A expenses for the three months ended September 30, 2007 were \$20.8 million, or 12.7% of sales, compared to \$18.2 million, or 12.7% of sales, for the three months ended September 30, 2006. SG&A expenses for the E&C segment were \$4.3 million for the three months ended September 30, 2007 compared to \$2.2 million for the three months ended September 30, 2006, an increase of \$2.1 million. The increase for the E&C segment was primarily the result of the inclusion in the 2006 period of \$2.5 million of income related to the settlement of a Hurricane Rita insurance claim offset by storm costs of \$0.2 million at a customer's project site. D&S segment SG&A expenses for the three months ended September 30, 2007 were \$8.1 million compared to \$6.9 million for the three months ended September 30, 2006, an increase of \$1.2 million. This increase was primarily attributable to higher employee-related and infrastructure costs to support business growth. SG&A expenses for the BioMedical segment were \$2.7 million for the three months ended September 30, 2007 compared to \$2.6 million for the three months ended September 30, 2006. Corporate SG&A expenses for the three months ended September 30, 2007 were \$5.6 million compared to \$6.4 million for the three months ended September 30, 2006. This decrease of \$0.8 million was primarily attributable to lower employee benefit costs offset partially by increased professional fees including Sarbanes-Oxley implementation costs.

***Amortization Expense***

Amortization expense for the three months ended September 30, 2007 was \$2.6 million, or 1.6% of sales, compared to \$4.3 million, or 3.0% of sales for the three months ended September 30, 2006. The decrease of \$1.7 million was due to certain intangible assets being fully amortized prior to July 1, 2007.

***Employee Separation and Plant Closure Costs***

For both the three months ended September 30, 2007 and 2006, employee separation and plant closure costs were \$0.1 million. The costs for both periods were related to the idle Plaistow, New Hampshire facility that has been held for sale. The sale of this facility and part of the land associated with it was completed in the fourth quarter of 2007.

***Loss on Disposal of Assets, Net***

For the three months ended September 30, 2007, the Company recognized a \$0.4 million loss on disposal related to a leased facility that was vacated by the Company's E&C segment

***Operating Income***

As a result of the foregoing, operating income for the three months ended September 30, 2007 was \$21.4 million, or 13.1% of sales, and represented an increase of \$4.5 million compared to operating income of \$16.9 million, or 11.8% of sales, for the same period in 2006.

***Net Interest Expense***

Net interest expense for the three months ended September 30, 2007 and 2006 was \$5.1 million and \$6.1 million, respectively. This decrease of \$1.0 million for the three months ended September 30, 2007 compared to the same period in 2006 was primarily attributable to decreased long-term debt outstanding as a result of voluntary principal

payments of \$40.0 million made on the Term Loan portion of our Senior Credit Facility funded primarily by proceeds from the Company's secondary stock offering completed in June 2007. This decrease was partially offset by higher interest rates on our Senior Credit Facility.

**Table of Contents*****Other Expense and Income***

Financing costs amortization were \$0.4 million for both the three months ended September 30, 2007 and 2006, respectively.

For the three months ended September 30, 2007, foreign currency gains were \$0.5 million as compared to minimal foreign currency gains for the same period in 2006. This increase in income was the result of the timing of transactions in currencies in other than functional currencies primarily in the D&S and BioMedical segments.

***Income Tax Expense***

Income tax expense of \$4.3 million and \$3.4 million for the three months ended September 30, 2007 and 2006, respectively, represents taxes on both U.S. and foreign earnings at an effective income tax rate of 26.3% and 32.5%, respectively. This decrease in the effective rate was primarily the result of the decision not to repatriate foreign excess cash to the U.S. in 2007, as originally planned. The full year effective tax rate for 2007 is now expected to approximate 31%.

***Net Income***

As a result of the foregoing, reported net income for the three months ended September 30, 2007 and 2006 was \$12.1 million and \$6.9 million, respectively.

**Results of Operations for the Nine Months Ended September 30, 2007 and 2006*****Sales***

Sales for the nine months ended September 30, 2007 were \$483.7 million compared to \$393.0 million for the nine months ended September 30, 2006, reflecting an increase of \$90.7 million, or 23.1%. E&C segment sales were \$168.8 million for the nine months ended September 30, 2007 compared with sales of \$138.1 million for the same period in 2006, which represented an increase of \$30.7 million, or 22.2%. This increase in sales resulted primarily from higher volume, particularly from larger projects, in both brazed aluminum heat exchangers and process systems, which were driven by continued growth in the liquefied natural gas ( LNG ) and natural gas segments of the hydrocarbon processing market. In addition, 2007 included \$16.8 million more of air-cooled heat exchanger sales from CSC, which was acquired in the second quarter of 2006. D&S segment sales increased \$53.7 million or 27.6% to \$248.4 million for the nine months ended September 30, 2007 from \$194.7 million for the nine months ended September 30, 2006. Bulk storage and packaged gas systems sales increased \$41.4 million and \$12.3 million, respectively, for the nine months ended September 30, 2007 compared to the same period in 2006. These increases were driven primarily by increased volume due to continued growth in the global industrial gas market and higher product pricing. Another contributing factor to the increased D&S sales for the nine months ended September 30, 2007 compared with the same period in 2006 was favorable foreign currency translation of approximately \$5.8 million as a result of the weakened U.S. dollar compared to the Euro and Czech Koruna. BioMedical segment sales increased \$6.3 million, or 10.5%, to \$66.5 million for the nine months ended September 30, 2007 compared to \$60.2 million for the nine months ended September 30, 2006. Biological storage systems sales increased \$5.6 million as a result of higher volume in the U.S. and international markets. MRI and other product sales increased \$1.3 million due to higher volume. Medical respiratory product sales decreased \$0.6 million as a result of decreased demand in the U.S. market due to changes in U.S. government reimbursement for liquid oxygen therapy systems partially offset by increased demand in the international markets.

***Gross Profit and Margin***

Gross profit for the nine months ended September 30, 2007 was \$136.5 million, or 28.2% of sales versus \$112.5 million, or 28.6% of sales, for the nine months ended September 30, 2006 and reflected an increase of \$24.0 million. E&C segment gross profit increased \$6.8 million in the 2007 period compared to the 2006 period primarily due to increased sales volume in brazed aluminum and air-cooled heat exchangers. The E&C segment gross profit margin increased 0.3 percentage points in 2007 primarily due to a favorable change in project mix for process systems. Gross profit for the D&S segment increased \$16.7 million in the 2007 period compared to the 2006 period primarily due to higher sales volume and to a lesser extent the timing of product price increases to absorb higher raw material costs in bulk storage and packaged gas systems. BioMedical gross profit increased \$0.5 million in the 2007 period compared to the 2006 period primarily due to higher sales volume. The BioMedical gross profit margin decreased 2.8 percentage points in 2007





**Table of Contents**

primarily due to increased raw material costs and to a lesser extent higher warranty costs for the three months ended September 30, 2007.

***SG&A***

SG&A expenses for the nine months ended September 30, 2007 were \$69.0 million, or 14.3% of sales, versus \$53.4 million, or 13.6% of sales, for the nine months ended September 30, 2006. SG&A expenses for the E&C segment were \$14.1 million for the nine months ended September 30, 2007 compared to \$10.3 million for the nine months ended September 30, 2006, an increase of \$3.8 million. The increase for the E&C segment was primarily the result of the inclusion in the 2006 period of \$2.5 million in income from the settlement of a Hurricane Rita insurance claim offset by storm costs of \$0.2 million at a customer's project site and in 2007 higher employee-related and infrastructure expenses to support business growth, increased commission expense due to higher sales volume and the inclusion of CSC for the entire nine months. D&S segment SG&A expenses for the nine months ended September 30, 2007 were \$21.5 million compared to \$18.7 million for the nine months ended September 30, 2006, an increase of \$2.8 million. This increase was primarily attributable to higher employee-related expenses to support business growth. SG&A expenses for the BioMedical segment were \$8.1 million for the nine months ended September 30, 2007, an increase of \$0.4 million compared to the nine months ended September 30, 2006. Corporate SG&A expenses for the nine months ended September 30, 2007 were \$25.3 million compared to \$16.7 million for the nine months ended September 30, 2006. This increase of \$8.6 million was primarily attributable to \$7.1 million in stock-based compensation expense related primarily to the vesting of the performance-based options in conjunction with the secondary stock offering completed in June 2007. Also contributing to the increase was the incurrence of approximately \$0.7 million of secondary stock offering expenses incurred in the second quarter of 2007 and higher infrastructure costs to support business growth.

***Amortization Expense***

Amortization expense for the nine months ended September 30, 2007 was \$8.3 million, or 1.7% of sales, compared to \$11.4 million, or 2.9% of sales for the nine months ended September 30, 2006. The decrease of \$3.1 million was due to certain intangible assets being fully amortized by December 31, 2006.

***Employee Separation and Plant Closure Costs***

For both the nine months ended September 30, 2007 and 2006, employee separation and plant closure costs were \$0.3 million. The costs for the both periods were related to the idle Plaistow, New Hampshire facility which has been held for sale. The sale of this facility and part of the land associated with it was completed in the fourth quarter of 2007.

***Loss on Disposal of Assets, Net***

For the nine months ended September 30, 2007, the Company recognized a \$0.5 million loss on disposal primarily related to a leased facility that was vacated by the Company's E&C segment

***Operating Income***

As a result of the foregoing, operating income for the nine months ended September 30, 2007 was \$58.5 million, or 12.1% of sales, and represented an increase of \$11.0 million compared to operating income of \$47.5 million, or 12.1% of sales, for the same period in 2006.

***Net Interest Expense***

Net interest expense for the nine months ended September 30, 2007 and 2006 was \$17.4 million and \$19.3 million, respectively. This decrease in interest expense of \$1.9 million for the nine months ended September 30, 2007 compared to the same period in 2006 was primarily attributable to decreased long-term debt outstanding as a result of voluntary principal payments of \$90.0 million made on the Term Loan portion of our Senior Credit Facility funded primarily by proceeds from warrant and option exercises, the Company's IPO in 2006 and proceeds from the secondary stock offering completed in June 2007. This decrease was partially offset by higher interest rates on our Senior Credit Facility and the additional interest incurred on the Subordinated Notes, since the exchange offering was not completed until April 2007.

***Other Expenses and Income***

For the nine months ended September 30, 2007 and 2006, financing costs amortization expense was \$1.2 million and \$1.1 million, respectively. This increase in amortization expense was attributable to additional deferred loan costs

incurred for the amendment on the Senior Credit Facility in connection with the IPO.

**Table of Contents*****Income Tax Expense***

Income tax expense of \$12.4 million and \$8.9 million for the nine months ended September 30, 2007 and 2006, respectively, represents taxes on both domestic and foreign earnings at an annual effective income tax rate of 31.0% and 32.5%, respectively. The decrease in the effective rate was primarily the result of the decision not to repatriate foreign excess cash to the U.S. in 2007, as originally planned.

***Net Income***

As a result of the foregoing, reported net income for the nine months ended September 30, 2007 and 2006 was \$27.7 million and \$18.3 million, respectively.

**Liquidity and Capital Resources*****Debt Instruments and Related Covenants***

As of September 30, 2007, the Company had \$80.0 million outstanding under the Term Loan portion of the Senior Credit Facility, \$170.0 million outstanding under the Subordinated Notes and \$32.7 million of letters of credit and bank guarantees supported by the revolving portion of the Senior Credit Facility. The Company is in compliance with all covenants, including its financial covenants, under the Senior Credit Facility and Subordinated Notes. Availability on the revolving portion of the Senior Credit Facility was \$82.3 million at September 30, 2007.

The registration rights agreement related to the Subordinated Notes required the Company to file an Exchange Offer Registration Statement and complete the exchange offer for the Subordinated Notes by August 14, 2006. Since the exchange offer was not completed when required, additional interest at a rate of 0.25% was incurred for the 90-day period commencing August 14, 2006, additional interest at a rate of 0.50% was incurred for the 90-day period commencing November 12, 2006 and additional interest at a rate of 0.75% was incurred for the 90-day period commencing February 10, 2007. The exchange offer was completed on April 6, 2007 and the additional interest ceased accruing as of that date.

***Sources and Use of Cash***

Cash provided by operations for the nine months ended September 30, 2007 was \$54.2 million compared with cash provided by operations of \$33.5 million for the nine months ended September 30, 2006. The increase in cash provided by operations in 2007 was primarily attributable to increased net income and non-cash operating activity, particularly stock-based compensation expense, and improved working capital.

Cash used in investing activities for the nine months ended September 30, 2007 was \$17.2 million compared to \$29.4 million for the nine months ended September 30, 2006. Capital expenditures for the nine months ended September 30, 2007 were \$15.6 million compared with \$13.5 million for the nine months ended September 30, 2006. Capital expenditures for 2007 were primarily for the E&C segment brazed aluminum heat exchanger facility expansion in La Crosse, Wisconsin and D&S segment expansion in China to support business growth. Capital expenditures during the same period in 2006 were primarily for expansion of existing facilities. For the nine months ended September 30, 2007, \$1.6 million of cash was used to purchase the remaining minority interest in Chart Ferox a.s. Also, for the nine months ended September 30, 2006, \$15.9 million of cash was used to purchase CSC.

For the nine months ended September 30, 2007, cash provided by financing activities was \$4.8 million compared to cash provided of \$3.2 million for the nine months ended September 30, 2006. For the nine months ended September 30, 2007, \$38.3 million of proceeds were received from the exercise of the underwriters' over-allotment option in conjunction with the Company's secondary stock offering completed in June and \$3.5 million in proceeds were received from the exercise of stock options. In May 2007, the Company received \$1.3 million in contributions from its joint venture partners to fund a new joint venture based in China for manufacture of cryogenic trailers. Also in 2007, \$40.0 million of cash was used for a voluntary principal prepayment under the Term Loan portion of our Senior Credit Facility. For the nine months ended September 30, 2006, \$211.7 million in proceeds was received from the IPO and warrant and option exercises. A cash dividend of \$150.3 million was paid in 2006 to stockholders existing immediately prior to the completion of the IPO. Also in 2006, \$55.0 million was used for voluntary principal prepayments under the Term Loan portion of our Senior Credit Facility.

***Cash Requirements***

The Company does not anticipate any unusual cash requirements for working capital needs, but expects to use \$5.0 to \$7.0 million of cash for capital expenditures for the remaining three months of 2007. A significant portion of the

capital expenditures are expected to be used for continued facility expansions and to increase capacity at the E&C segment La Crosse, Wisconsin facility and the D&S segment China, Czech Republic and New Prague, Minnesota facilities. Management

**Table of Contents**

believes that these expansions are necessary to support our current backlog levels and our expected growth due to an increase in global demand for our products.

For the remaining three months of 2007, cash requirements for debt service are forecasted to be approximately \$9.2 million for scheduled interest payments under our Senior Credit Facility and the Subordinated Notes. We are not required to make any scheduled principal payments during the remaining three months of 2007 under the Term Loan portion of the Senior Credit Facility or Subordinated Notes, but we may consider making voluntary principal payments on our Senior Credit Facility or repurchasing our Subordinated Notes on the open market to the extent permitted by our debt covenants with excess cash flow that is generated. For the remainder of 2007, we expect to use approximately \$3.6 million of cash for both U.S. and foreign income taxes and contribute approximately \$0.2 million of cash to our four defined benefit pension plans to meet ERISA minimum funding requirements.

**Orders and Backlog**

We consider orders to be those for which we have received a firm signed purchase order or other written contractual commitment from the customer. Backlog is comprised of the portion of firm signed purchase orders or other written contractual commitments received from customers that the Company has not recognized as revenue under the percentage of completion method or based upon shipment. Backlog can be significantly affected by the timing of orders for large projects, particularly in the E&C segment, and it is not necessarily indicative of future backlog levels or the rate at which backlog will be recognized as sales. Orders included in our backlog may include customary cancellation provisions under which the customer could cancel part or all of the order at times subject to the payment of certain costs and/or penalties, if applicable. Backlog as of September 30, 2007 was \$426.1 million compared to \$415.3 million as of June 30, 2007.

The following table sets forth orders and backlog by segment for the periods indicated:

|                          | <b>Three Months Ended</b> |                 |
|--------------------------|---------------------------|-----------------|
|                          | <b>September</b>          |                 |
|                          | <b>30,</b>                | <b>June 30,</b> |
|                          | <b>2007</b>               | <b>2007</b>     |
| <b>Orders</b>            |                           |                 |
| Energy and Chemicals     | \$ 71,453                 | \$ 146,447      |
| Distribution and Storage | 81,771                    | 75,997          |
| BioMedical               | 22,202                    | 21,014          |
| Total                    | \$ 175,426                | \$ 243,458      |
| <b>Backlog</b>           |                           |                 |
| Energy and Chemicals     | \$ 325,717                | \$ 315,034      |
| Distribution and Storage | 90,802                    | 92,586          |
| BioMedical               | 9,534                     | 7,653           |
| Total                    | \$ 426,053                | \$ 415,273      |

E&C orders for the three months ended September 30, 2007 were \$71.5 million compared to \$146.4 million for the three months ended June 30, 2007. E&C backlog totaled \$325.7 million at September 30, 2007 compared to \$315.0 million at June 30, 2007. The decrease in orders of \$74.9 million, or 51.2%, was primarily attributable to the receipt of process system orders totaling in excess of \$100.0 million in the second quarter of 2007 for four LNG liquefaction trains to be installed in Southeast Asia. In the third quarter of 2007, an additional order of over \$20.0 million was received for this LNG project in Southeast Asia for externally purchased components.

D&S orders for the three months ended September 30, 2007 were \$81.8 million compared to \$76.0 million for the three months ended June 30, 2007. D&S backlog totaled \$90.8 million at September 30, 2007 compared to

\$92.6 million at June 30, 2007. The D&S backlog declined primarily due to the higher sales for the three months ended September 30, 2007. Overall, D&S orders have remained strong in recent quarters due to continued demand in the global industrial gas market. Both bulk storage systems and packaged gas systems orders for the three months ended September 30, 2007 have increased compared to the three months ended June 30, 2007.

BioMedical orders for the three months ended September 30, 2007 were \$22.2 million compared to \$21.0 million for the three months ended June 30, 2007. BioMedical backlog at September 30, 2007 totaled \$9.5 million compared to \$7.7 million at June 30, 2007. The increase in orders of \$1.2 million, or 5.7%, was primarily due to continued penetration of international markets across all product lines.

**Table of Contents**

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements as defined in the Securities Act.

**Application of Critical Accounting Policies**

The Company's unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. As such, some accounting policies have a significant impact on amounts reported in these unaudited condensed consolidated financial statements. A summary of those significant accounting policies can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, judgment is used in areas such as revenue recognition for long-term contracts, determining the allowance for doubtful accounts, inventory valuation reserves, goodwill, indefinite lived intangibles, environmental remediation obligations, product warranty costs, debt covenants, pensions and deferred tax assets. There have been no significant changes in accounting policies since December 31, 2006, except for the adoption on January 1, 2007 of FIN 48 as it relates to the accounting for income taxes. The adoption of FIN 48 did not have a material effect on the Company's financial position, results of operations or cash flows.

**Forward-Looking Statements**

The Company is making this statement in order to satisfy the "safe harbor" provisions contained in the Private Securities Litigation Reform Act of 1995. This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements relating to our business. In some cases, forward-looking statements may be identified by terminology such as "may," "will," "should," "expects," "anticipates," "believes," "projects," "forecasts," "continue," or the negative of such terms or comparable terminology. Forward-looking statements contained herein (including future cash contractual obligations) or in other statements made by us are made based on management's expectations and beliefs concerning future events impacting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by forward-looking statements. We believe that the following factors, among others (including those described in our Risk Factors disclosure), could affect our future performance and the liquidity and value of our securities and cause our actual results to differ materially from those expressed or implied by forward-looking statements made by us or on our behalf:

the cyclical nature of the markets which we serve;

the loss of, or a significant reduction in purchases by, our largest customers;

competition in our markets;

our compliance obligations with the Sarbanes-Oxley Act of 2002;

general economic, political, business and market risks associated with our non-U.S. operations;

our ability to successfully manage our growth;

the loss of key employees;

the pricing and availability of raw materials and our ability to manage our fixed-price contract exposure, including exposure to fixed pricing in long-term customer contracts;

our ability to successfully acquire or integrate companies that provide complementary products or technologies;

our ability to continue our technical innovation in our product lines;



the impairment of our goodwill and other indefinite-lived intangible assets;

the costs of compliance with environmental, health and safety laws and responding to potential liabilities under these laws;

the insolvency of our formerly consolidated subsidiary, Chart Heat Exchangers Limited, or CHEL, and CHEL's administration proceedings in the United Kingdom, including claims that may be asserted against us with respect to CHEL's obligations;

**Table of Contents**

litigation and disputes involving us, including the extent of product liability, warranty, pension and severance claims asserted against us;

labor costs and disputes;

our relations with our employees;

our funding requirements in connection with our defined benefit pension plans;

fluctuations in foreign currency exchange and interest rates;

disruptions in our operations due to hurricanes;

our ability to protect our intellectual property and know-how;

regulations governing the export of our products;

additional liabilities related to taxes; and

risks associated with our substantial indebtedness, leverage, debt service and liquidity.

There may be other factors that may cause our actual results to differ materially from the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date of this Quarterly Report and are expressly qualified in their entirety by the cautionary statements included in our Annual Report on Form 10-K for 2006 and our definitive prospectus filed with the Securities and Exchange Commission on June 7, 2007. We undertake no obligation to update or revise forward-looking statements, which may be made to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

In the normal course of business, the Company's operations are exposed to continuing fluctuations in foreign currency values and interest rates that can affect the cost of operating and financing. Accordingly, the Company addresses a portion of these risks through a program of risk management.

The Company's primary interest rate risk exposure results from the various floating rate pricing mechanisms on the Senior Credit Facility. If interest rates were to increase 200 basis points (2 percent) from September 30, 2007 rates, and assuming no changes in debt from the September 30, 2007 levels, the additional annual expense would be approximately \$1.6 million on a pre-tax basis.

The Company has assets, liabilities and cash flows in foreign currencies creating exposure to foreign currency exchange fluctuations in the normal course of business. Chart's primary exchange rate exposure is with the Euro, the British pound, the Czech koruna and the Chinese yuan. Monthly measurement, evaluation and forward exchange rate contracts are employed as methods to reduce this risk. The Company enters into foreign exchange forward contracts to hedge anticipated and firmly committed foreign currency transactions. Chart does not use derivative financial instruments for speculative or trading purposes. The terms of the contracts are one year or less. The Company held immaterial positions in foreign exchange forward contracts at September 30, 2007.

**Item 4. Controls and Procedures**

As of September 30, 2007, an evaluation was performed, under the supervision and with the participation of the Company's management including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities and Exchange Act of 1934, as amended (the Exchange Act). Based upon that evaluation, such officers concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act (1) is recorded,

processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms and (2) is accumulated and communicated to the Company's management including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

There were no changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

**PART II. OTHER INFORMATION**

**Item 1A. Risk Factors**

There have not been any material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, except to the extent set forth under the captions "Risk Factors - Risks Related to our Business" and "Risk Factors - Risks Related to our Leverage" in the Company's definitive prospectus filed with the Securities and Exchange Commission under Rule 424 on June 7, 2007.

**Table of Contents**

**Item 6. Exhibits**

The following exhibits are filed with this report:

- 10.1 Form of Performance Unit Agreement (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated August 2, 2007
- 10.2 Form of Nonqualified Stock Option Agreement (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated August 2, 2007
- 31.1 Rule 13a-14(a) Certification of Chief Executive Officer
- 31.2 Rule 13a-14(a) Certification of Chief Financial Officer
- 32.1 Section 1350 Certification of Chief Executive Officer
- 32.2 Section 1350 Certification of Chief Financial Officer

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chart Industries, Inc.

(Registrant)

Date: November 13, 2007

By: /s/ Michael F. Biehl

Michael F. Biehl  
Executive Vice President, Chief Financial Officer and  
Treasurer  
(Principal Financial Officer)  
(Duly Authorized Officer)

32